Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: Prospects for drug development

S. M. Sebti, A. D. Hamilton

Research output: Contribution to journalReview articlepeer-review

Abstract

Inhibition of farnesyltransferase (FTase) has been thoroughly investigated as a strategy to discover novel anticancer drugs; the reason for this being that the oncoprotein Ras requires farnesylation for its cancer-causing activity. Several highly potent and selective FTase inhibitors have been made and show excellent antitumour activity against human rumours in animal models without toxicity to normal cells. However, resistance of the most frequently mutated form of Ras, K-Ras, to FTase inhibitors and its alternative prenylation by geranylgeranyltransferase I (GGTase I) have cast doubts on whether K-Ras is the target for FTase inhibitors. This update focuses on issues of critical importance to the further development of FTase inhibitors as anticancer agents. Alternative prenylation of K-Ras by GGTase I as a mechanism of resistance to FTase inhibitors, targets for FTase inhibitors other than K-Ras and the relevance of GGTase I inhibitors as antitumour agents will be discussed.

Original languageEnglish (US)
Pages (from-to)1711-1714
Number of pages4
JournalExpert Opinion on Investigational Drugs
Volume6
Issue number11
DOIs
StatePublished - 1997

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Anticancer activity of farnesyltransferase and geranylgeranyltransferase I inhibitors: Prospects for drug development'. Together they form a unique fingerprint.

Cite this